|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 2 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation显示文摘 | Inwald DP McDowall A Peters MJ | 2003 | Cir Res2003，92，9： | 1 |
| 3 | EULAR evidence-basedrecommendations for cardiovascular risk management in patientswith rheumatoid arthritis and other forms of inflammatory arthritis显示文摘 | Peters MJ Symmons DP McCarey D | 2010 | Ann Rheum Dis2010，69，2： | 1 |
| 4 | EULAR evidence-based rec- ommendations for cardiovascular risk management in patients with rheu- matoid arthritis and other forms of inflammatory arthritis 显示文摘 | Peters M J Symmons DP McCarey D | 2010 | Ann Rheum Dis2010，69，2： | 1 |
| 5 | Esophageal perforation: surgical, endoscopic and medical management strategies 显示文摘 | Sepesi B Raymond DP Peters JH | 2010 | Curr Opin Gastroenterol2010，26，4： | 1 |
| 6 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwald DP McDowall A Peters M J | 2003 | Cir Res2003，92，9： | 1 |
| 7 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwaid DP McdowaU A Peters MJ | 2003 | Circ Res2003，92，9： | 1 |
| 8 | Calcium phosphate drug delivery system: Influence of local zoledronate re- lease on bone implant osteointegration显示文摘 | Peter B Pioleni DP Laib S | 2005 | Bone2005，36，1： | 1 |
| 9 | The Comfort Behavior Scale:a tool for assessing pain and sedation in infants显示文摘 | Van DM Peters JW Van DP | 2005 | Am J Nuts2005，105，1： | 1 |
| 10 | EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis显示文摘 | Peters MJ Symmons DP Mc Carey D | 2010 | Ann Rheum Dis2010，69，： | 1 |
| 11 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwald DP McDowall A Peters M J | 2003 | Circ Res2003，92，9： | 1 |
| 12 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation显示文摘 | Inwald DP Mc Dowall A Peters MJ | 2003 | Circ Res2003，92，9： | 1 |
| 13 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation显示文摘 | Inwald DP McDowall A Peter MJ | 2003 | Circ Res2003，92，： | 1 |
| 14 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwald DP McDowall A Peters MJ | 2003 | Circ Res2003，92，： | 1 |
| 15 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation显示文摘 | Inwald DP McDowall A Peters MJ Callard RE and Klein NJ | 2003 | Cir Res2003，92，9： | 1 |
| 16 | CD40 is consrirutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwald DP McDowall A Peters MI | 2003 | Cir Res2003，92，： | 1 |
| 17 | Decreased slow wave sleep and enlarged lateral ventricles in schizophrenia 显示文摘 | Kammen DP Kammen WB Peters J | 1988 | Neuropsychopharmacology1988，1，： | 1 |
| 18 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation 显示文摘 | Inwald DP McDowall A Peters MJ | 2003 | Circ Res2003，92，9： | 1 |
| 19 | CD40 is novel constitutively expressed on platdets and provides a novel mechanism for platelet activation显示文摘 | Inwald DP McDowall A Peters MJ | 2003 | Cir Res2003，92，： | 1 |
| 20 | Homozygosity (E140K) in SCO2 causes delayed infantile onset of cardiomyopathy and neuropathy 显示文摘 | Jaksch M Horvath R Horn N Auer DP Macmillan C Peters J | 2001 | Neurology2001，57，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员